ArticlePLoS neglected tropical diseases2025
Epidemiology and severity risk factors of dengue virus infection during the 2023-2024 outbreak in Colombia.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Unresolved questions in pediatric dengue: from disease mechanisms to prevention.Current opinion in infectious diseases · 2026Review
- A multicenter prospective observational multi-omics study protocol to identify biomarkers for severe dengue: COMBAT study clinical protocol.BMC infectious diseases · 2026Observational
- Monocyte TLR2/4 as predictive biomarkers for progression from dengue warning signs to severe disease.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionDuring 2023-2024, the Americas faced its largest dengue epidemic to date. We used a detailed dengue classification to identify patients with serious manifestations of dengue and aimed to describe risk factors for occurrence.
methodsFrom April 2023 to September 2024, we conducted a prospective in-hospital active case-finding cohort study at the Hospital Universitario del Valle (HUV) in Colombia, enrolling patients of all ages with virologically confirmed dengue (VCD). Sociodemographic and clinical data were collected, and the dengue virus (DENV) genome was sequenced for serotyping and genotyping. Multivariable logistic regression modeling identified factors associated with "serious manifestations of dengue", defined as severe dengue (2009 WHO classification) or dengue with warning signs (DwWS) with a more severe course, including vascular leakage (increases in hematocrit >20%, pleural effusion or ascites with hemodynamic/respiratory compromise); bleeding with hemodynamic instability or requiring blood transfusion; thrombocytopenia <20,000 or organ dysfunction (myocarditis, encephalitis or liver failure).
resultsAmong 600 patients (median age 13 years, 55% male), serotyping and genotyping were possible for 340 (57%) and 296 (49%) samples, respectively. The most frequent serotypes were DENV-2 (32%) and DENV-3 (15%), and lineages 2II_F.1.1.2 (19%) and 3III_C.1 (15%). Serious manifestation of dengue occurred in 167 (28%) patients, including 22 with severe dengue and 145 DwWS cases with a more severe course. Independent risk factors for serious manifestations of dengue were living outside of city limits, presenting with edema and higher leukocyte counts, whereas lower odds were observed for patients with higher platelets and lymphocyte counts, and infections other than DENV-2. History of dengue infection showed no significant effect on the risk of serious clinical manifestations across the different serotypes.
conclusionThis outbreak involved multiple dengue virus serotypes and genotypes and predominantly affected children and adolescents. Identification of the risk factors described here could enable earlier recognition of patients with serious dengue manifestations. In this cohort, serotype 2 was associated with higher risk but given the unpredictable dynamics of severe dengue, efforts should strive for tetravalent protection, regardless of prior dengue exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.